RxDoctor Payments Data

Christopher Hofelich, DO

Interventional Cardiology · Jeffersonville, INNPI 1992805493

Payments from drug & device makers

$6,169in general payments, 2019–2025

Across 311 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$745
  • Osprey Medical Inc$694
  • Novartis$609
  • E.r. Squibb & Sons, L.L.C.$506
  • Johnson & Johnson$474
  • Boston Scientific$375
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$5008%
  • Food & beverage$5,64992%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,169 in reported general payments places this provider in the 40th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$230,572
Medicare patients
887
Services billed
3,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$159,382
XareltoRivaroxaban67$74,678
BrilintaTicagrelor86$68,249
EntrestoSacubitril/Valsartan39$44,357
Repatha SureclickEvolocumab32$21,922
Prasugrel Hcl40$8,764
EdarbyclorAzilsartan Med/Chlorthalidone17$4,524
Metoprolol Succinate377$4,058
Ranolazine ErRanolazine47$2,919
Icosapent Ethyl24$2,743
Enoxaparin Sodium16$2,742
ClopidogrelClopidogrel Bisulfate295$2,601
Nebivolol Hcl69$2,450
Atorvastatin Calcium319$1,981
Isosorbide Mononitrate ErIsosorbide Mononitrate153$1,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$236$159,382126 claims
Johnson & JohnsonXarelto$474$74,67867 claims
AstraZenecaBrilinta$345$68,24986 claims
NovartisEntresto$609$44,35739 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$16$4,52417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →